Form 4: Merus VP Controller Sells Shares in Genmab Tender Offer

Merus N.V.'s VP Controller, Harry Shuman, disposed of all his common shares and cancelled all his share options as part of Genmab's tender offer at $97.00 per share.

Summary

• Harry Shuman, VP Controller and PAO of Merus N.V., reported changes in beneficial ownership.
• Disposed of 11,002 common shares at $97.00 per share on December 12, 2025.
• Disposed of 112,370 share options with various exercise prices (ranging from $13.23 to $41.65) on December 12, 2025.
• These transactions were part of a tender offer by Genmab A/S and its subsidiary Genmab Holding II B.V. for Merus N.V. shares.
• The options were cancelled for a cash payment equal to the difference between the $97.00 offer consideration and the option's exercise price, multiplied by the number of underlying shares.
• Following these transactions, Harry Shuman beneficially owns 0 common shares and 0 derivative securities.

Sentiment

Score: 7

Explanation: The filing reports the expected disposition of shares and options by an insider as part of a tender offer. This is a neutral event for the company's ongoing operations but positive for the insider due to the cash payout, reflecting a successful acquisition process.

Positives

• The reporting person received a cash payment of $97.00 per common share, providing liquidity.
• Share options were monetized for cash, reflecting the intrinsic value (offer price minus exercise price).
• The tender offer provides a defined exit and liquidity event for shareholders and option holders.

Negatives

• The reporting person no longer holds any direct equity or derivative interest in Merus N.V.
• Loss of potential future upside if Merus N.V.'s share price were to exceed the tender offer price significantly in the long term, had the company remained independent.

Future Outlook

No specific future outlook or guidance is provided in this Form 4, as it primarily reports an insider transaction related to an acquisition.

Industry Context

This transaction reflects a common strategy in the biotechnology or pharmaceutical industry where larger companies acquire smaller, innovative firms, often through tender offers, to gain access to their pipeline, technology, or market position. Genmab's acquisition of Merus N.V. indicates consolidation or strategic expansion within the sector.

Comparison to Industry Standards

• The tender offer price of $97.00 per share would need to be compared to Merus N.V.'s historical trading prices, analyst price targets, and valuations of comparable M&A transactions in the biotech sector to assess its fairness.
• For example, recent biotech acquisitions like Pfizer's acquisition of Seagen or AbbVie's acquisition of ImmunoGen involved significant premiums over pre-announcement share prices, which would be a benchmark for evaluating the $97.00 offer.
• The monetization of options at (Offer Price Exercise Price) is a standard practice in tender offers for public companies, ensuring option holders receive intrinsic value.

Stakeholder Impact

• Shareholders: Those who tendered shares received $97.00 per share in cash, providing liquidity and a defined return.
• Option Holders: Option holders received cash for the intrinsic value of their options, monetizing their equity incentives.
• Employees: While not explicitly stated, the acquisition by Genmab A/S could lead to integration efforts impacting employees.

Next Steps

• Payment of the Offer Consideration to the reporting person as soon as practicable following the Acceptance Time (December 12, 2025).

Key Dates

Recommendation

The filing details an insider's participation in a tender offer where Merus N.V. is being acquired by Genmab A/S. Since the acquisition is proceeding and the shares are being tendered at a fixed price of $97.00, there is no further upside potential from holding the stock beyond the tender offer price. Investors who have not yet tendered their shares should consider doing so to realize the cash value. For those who have already tendered, the transaction is complete. Therefore, a 'hold' recommendation implies holding until the tender is complete or tendering if not already done, as the company's independent trading future is limited.

Keywords

Merus N.V., MRUS, Genmab A/S, Tender Offer, Share Disposition, Option Cancellation, Insider Transaction, Form 4, Beneficial Ownership, Harry Shuman